What Shattuck Labs Stock Topped the Market on Monday
Two analysts weighed in with new takes on the biotech.
Overview
Not one, but two, analysts published new takes on Shattuck Labs (NASDAQ: STTK) in the past few days. Since both prognosticators were optimistic about the clinical-stage biotech's future, investors were cheered enough to buy into its stock. On Monday, this helped propel it to a nearly 5% gain that trading session.
Over the weekend, TD Cowen's Stacy Ku assumed coverage of Shattuck, flagging it as a buy. Two days later, Martin Auster of Raymond James initiated coverage of the biotech and had a more positive view -- he rated it a strong buy at a price target of $18 per share. This is over twice its most recent closing price of $7.90.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.